On February 16, 2022 Predicine, a global molecular insights company, reported that it will present six posters highlighting clinical utility of Predicine’s full suite of liquid- and tissue-based comprehensive genomic profiling solutions at the ASCO (Free ASCO Whitepaper) Genitourinary Cancers Symposium being held February 17-19, 2022, in San Francisco (Press release, Predicine, FEB 16, 2022, View Source [SID1234608198]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The posters are focused on the full spectrum of GU indications, including muscle invasive bladder cancer (MIBC), metastatic castration-resistant prostate cancer (mCRPC), renal cell carcinoma (RCC) and locally advanced and metastatic Upper Tract Urothelial Carcinomas (UTUC). Highlights from the posters include a clinical utility study of PredicineBEACONTM, applied to a urine-based, tissue-agnostic minimal residual diseases (MRD) solution in bladder cancer, as well as blood-based detection of DNA damage repair (DDR) deficiencies in prostate cancer.
The posters to be presented are as follows:
Development and Clinical Application of PredicineBEACONTM Next-Generation Minimal Residual Disease Assay for Genitourinary Cancers.
Novel Use of ctDNA to Identify Locally Advanced and Metastatic Upper Tract Urothelial Carcinoma.
Longitudinal Personalized Urinary Tumor DNA Analysis In Muscle Invasive Bladder Cancer From the Neoadjuvant Immunotherapy Trial RJBLC-I2N003.
Molecular Characterization of Renal Cell Carcinoma with Venous Tumor Thrombus: Genomic Aberrations with Renal Vein Wall Invasion.
Prognostic and Predictive Utility of DNA Damage Response (DDR) Aberrations Detected in cfDNA in Metastatic Castration-Resistant Prostate Cancer (mCRPC).
Age-based Assessment Of Cell-Free DNA Genomic Profiles in Metastatic Castration-Resistant Prostate Cancer (mCRPC)
The full posters can be found at the ASCO (Free ASCO Whitepaper) Genitourinary Cancer Symposium website here.
"Predicine is pleased to present six liquid biopsy and tissue NGS studies at ASCO (Free ASCO Whitepaper)-GU 2022. As part of Predicine’s Phoenix Program, we are committed to building the clinico-genomic knowledgebase in the full spectrum of GU cancers by leveraging Predicine’s proprietary next-generation liquid biopsy technology platform, especially in the MRD space. The data presented demonstrated the great promise of liquid biopsy in personalized cancer care, clinical trials and CDx development," said Dr. Shidong Jia, Founder and Global CEO of Predicine.
Additional peer-reviewed publications on cancer can be found on Predicine’s website here.